Rivastigmine Teva

RSS

rivastigmine

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Rivastigmine Teva has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 27/09/2012

Authorisation details

Product details
Name
Rivastigmine Teva
Agency product number
EMEA/H/C/001044
Active substance
rivastigmine
International non-proprietary name (INN) or common name
rivastigmine
Therapeutic area (MeSH)
  • Dementia
  • Alzheimer Disease
  • Parkinson Disease
Anatomical therapeutic chemical (ATC) code
N06DA03
GenericGeneric

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Teva Pharma B.V.
Revision
4
Date of issue of marketing authorisation valid throughout the European Union
17/04/2009
Contact address
Computerweg 10
NL-3542 DR Utrecht
The Netherlands

Product information

10/09/2012 Rivastigmine Teva - EMEA/H/C/001044 - IB/0008/G

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Anticholinesterases

Therapeutic indication

Symptomatic treatment of mild to moderately severe Alzheimer's dementia.

Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

Assessment history

How useful was this page?

Add your rating